Fig. 1
From: Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
O-GlcNAcylation associated with DAC resistance in MDS/AML. A mRNA level of TWIST1 in AML patients vs HD in TCGA database. B, C qRT-PCR analysis of OGT mRNA (B) and Elisa analysis of O-GlcNAc level (C) in CD34+ cells of DAC-R and DAC-NR. D Cell proliferation assay. CD34+ cells were derived from MDS patients who are non-responsive to DAC and treated with DAC (20 ng/mL) and OSMI-1 (10 μg/mL) or PUGNAc (100 μM) for 48 h. E Cell proliferation assay. KG1a-DAC-R cells were treated with DAC (20 ng/mL) and OSMI-1 (10 μg/mL) or PUGNAc (100 μM) for 48 h. *p < 0.05, ***p < 0.001